OBJECTIVES: To assess treatment patterns and associated patient characteristics among PD patients in a multi-center setting in Spain, and generate estimates at country-level. METHODS: NeuroMonitor is an annual study conducted among neurologists in hospitals and private practices to collect chart data (disease/patient characteristics & treatment patterns) on patients receiving medications to treat neurologic conditions during the study window/encounter. Current analysis of PD patients in Spain utilized 2006 data from 102 neurologists & 1030 patient charts. A multi-stage weighting method at physician/patient level was employed to extrapolate data to Spain population. RESULTS: Among patients receiving neurologic agents in 2006, over 85,000 patients were estimated to have PD (average age: 71yrs; female: 40%; disease stages per H&Y scale, I: 13%, II: 37%, III: 34%, IV: 12%, V: 1%). Majority (87%) of PD-patients were diagnosed by neurologists, and 42%, 21% & 37% of patients were diagnosed within 1-yr, 1-2yrs & >2-yrs respectively. Key comorbidities included: Hypertension (53%), dyslipidemia (29%), diabetes (26%), osteoarthritis (24%), depression (26%) & anxiety/dementia (12% each). Majority (98%) of PD-patients received anti-parkinson's medications, with sparse use of antidepressants (2%) and anticholinergics/antipsychotics/anti-alzheimers/hypnotics-sedatives (1% each). Among those using anti-parkinson's medication, utilization patterns varied by disease severity – levadopa-based: total-77%, mild-62%, moderate-91%, severe-96%, cabergoline: total-15%, mild-12%, moderate-16%, severe-20%, pramipexole: total-14%, mild-16%, moderate-11%, severe-12%, ropinirol: total-11%, mild-10%, moderate-11%, severe-18%, selegiline: total-9%, mild-9%, moderate-8%, severe-9%, entacapone: total-7%, mild-3%, moderate-8%, severe-22%, rasagiline: total-5%, mild-6%, moderate-4%, severe-5%. CONCLUSION: Almost half of PD patients were diagnosed within last 1-yr and majority had moderate disability. In spite of prevalence of psychiatric comorbidities, only few patients were on appropriate concomitant medications. Levodopa-based PD regimen use was widely prevalent, followed by dopamine-agonists; extent of use differed by disease severity. Further research is warranted to assess the impact of these patterns on long-term outcomes.